26.34

1.82% 0.47

Lenz Therapeutics Inc (LENZ)

Overview News Price History Discussions Forecast

Lenz Therapeutics Inc stock is traded at $26.34, with a volume of 226.52K. It is up +1.82% in the last 24 hours and up +28.99% over the past month. LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.

Previous Close:

$25.87

Open:

$26.34

24h Volume:

226.52K

Relative Volume:

0.99

Market Cap:

$813.11M

Revenue:

Net Income/Loss:

$-69.47M

P/E Ratio:

-4.7058

EPS:

-5.5973

Net Cash Flow:

$-73.92M

1W Performance:

-10.77%

1M Performance:

+28.99%

6M Performance:

-24.89%

1Y Performance:

+71.04%

1-Day Range:

$24.86

$26.44

1-Week Range:

$22.52

$29.70

52-Week Range:

$14.42

$38.93

Lenz Therapeutics Inc Stock (LENZ) Company Profile

Name

Lenz Therapeutics Inc

Sector

Healthcare (1153)

Industry

Biotechnology (676)

Phone

858-925-7000

Address

201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH

Employee

Twitter

Next Earnings Date

Latest SEC Filings

LENZ's Discussions on Twitter

Compare LENZ with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LENZ Lenz Therapeutics Inc	26.34	813.11M	0	-69.47M	-73.92M	-5.5973
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-14-25	Resumed	Piper Sandler	Overweight
Mar-18-25	Initiated	TD Cowen	Buy
Sep-27-24	Initiated	Raymond James	Outperform
Aug-12-24	Initiated	H.C. Wainwright	Buy
Apr-15-24	Initiated	Leerink Partners	Outperform
Apr-15-24	Initiated	William Blair	Outperform
Apr-10-24	Initiated	Citigroup	Buy
Mar-27-24	Initiated	Piper Sandler	Overweight
Feb-23-23	Downgrade	BofA Securities	Neutral → Underperform
Feb-23-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-23-23	Downgrade	Cowen	Outperform → Market Perform
Jan-25-23	Downgrade	BTIG Research	Buy → Neutral
Jan-18-23	Downgrade	BofA Securities	Buy → Neutral
Jan-06-23	Downgrade	BMO Capital Markets	Outperform → Market Perform
Jan-06-23	Downgrade	SVB Leerink	Outperform → Mkt Perform
Sep-15-22	Initiated	Cantor Fitzgerald	Overweight
Jun-17-22	Initiated	BMO Capital Markets	Outperform
Apr-14-22	Initiated	BTIG Research	Buy
Mar-22-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-18-22	Initiated	RBC Capital Mkts	Sector Perform
Jul-20-21	Initiated	Morgan Stanley	Overweight
Jul-20-21	Initiated	SVB Leerink	Outperform

View All

Lenz Therapeutics Inc Stock (LENZ) Latest News

May 09, 2025

Lenz Therapeutics’ Earnings Call Highlights Strong Outlook - TipRanks

May 09, 2025

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Acquired by Wells Fargo & Company MN - Defense World

May 09, 2025

LENZ Grants Lotus Licensing Rights to Presbyopia Treatment in South Korea, Southeast Asia - marketscreener.com

May 09, 2025

LENZ Therapeutics inks deal with Lotus for eye treatment - Investing.com

May 09, 2025

LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia - The Manila Times

May 09, 2025

May 08, 2025

Earnings call transcript: LENZ Therapeutics’ Q1 2025 results show innovation drive - Investing.com

May 08, 2025

May 07, 2025

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Consensus Rating of “Buy” by Brokerages - Defense World

May 07, 2025

LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights - Enidnews.com

May 07, 2025

Market Recap Check: LENZ Therapeutics Inc (LENZ)’s Negative Finish at 25.89, Up/Down -11.03 - DWinneX

May 07, 2025

May 06, 2025

LENZ Therapeutics Announces Participation in BofA Securities 2025 Health Care Conference - Nasdaq

May 06, 2025

LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference - The Manila Times

May 06, 2025

First-Ever Presbyopia Eye Drop Treatment: LENZ Therapeutics Reveals Latest Progress at BofA Conference - Stock Titan

May 06, 2025

Barclays PLC Increases Holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World

May 06, 2025

May 04, 2025

JPMorgan Chase & Co. Purchases 2,643 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World

May 04, 2025

May 02, 2025

Renaissance Technologies LLC Sells 23,900 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World

May 02, 2025

May 01, 2025

Legal & General Group Plc Has $252,000 Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World

May 01, 2025

Apr 30, 2025

LENZ Therapeutics to Host Webcast on First Quarter 2025 Financial Results and Corporate Developments - Nasdaq

Apr 30, 2025

LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025 - The Manila Times

Apr 30, 2025

Revolutionary Presbyopia Treatment Developer LENZ Therapeutics Announces Q1 2025 Earnings Date - Stock Titan

Apr 30, 2025

Apr 28, 2025

Presbyopia Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, NICE Approvals, Mechanism of Action, ROA, IND, NDA Approval and Companies by DelveInsight - The Globe and Mail

Apr 28, 2025

Apr 26, 2025

ProfittoPath - TradingView

Apr 26, 2025

Apr 25, 2025